Starling Oncology, Inc.
STLN· Nasdaq
STLNStarling Oncology, Inc.
Filed Aug 9, 2022 · 10-Q · 40 days after period end · 0001628280-22-021938
| Metric | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|
| Revenue | $60.92M | $49.84M | — |
| Net Income | -$5.45M | -$6.12M | -$115.74K |
| EPS Diluted | -$0.06 | $0.05 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 9, 2022 · 40 d after period end
